New drug ZULRESSO offers hope for moms with postpartum depression

NCT ID NCT03924492

APPROVED_FOR_MARKETING Symptom relief Sponsor: Supernus Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This program provides early access to ZULRESSO (brexanolone) for adult women with postpartum depression before the drug is widely available. Eligible women receive a one-time injection under medical supervision. The goal is to help ease severe depression symptoms quickly.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: brexanolone (ZULRESSO) injection
What this could lead to: If successful, this program could provide a new treatment option for women with postpartum depression, potentially easing severe symptoms quickly.
What could go wrong: This is an expanded access program, not a controlled trial, so results may not be generalizable. Risks include side effects like sedation or sudden loss of consciousness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for POSTPARTUM DEPRESSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

postpartum depression

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

POSTPARTUM DEPRESSION

More trials for these conditions

Other studies related to the condition(s) this trial covers.